Oxford Biomedica, AstraZeneca enter new deal for Covid-19 vaccine
According to the new deal, AstraZeneca will have access to Covid-19 vaccine manufacturing at Oxford Biomedica’s Oxbox facility.
Company News
Latest in
Company News
Blueprint Medicines announces financing partnerships for $1.25bn
At the closing of the deal, Blueprint will get a total of $575m in cash.
Twist and Ildong to develop antibodies for immuno-oncology applications
Under the deal, Twist will receive upfront, milestone and royalty payments as well as annual maintenance fees.
Pfizer seeks approval from US FDA for Covid-19 treatment
The filing is based on non-clinical and clinical data for Paxlovid and also comprised data from the Phase II/III EPIC-HR…
Eczacıbaşı to acquire Turkish pharma company Gensenta for $135m
Following the acquisition, Amgen Turkey will maintain its operations and serve its patients in the region.
HDT Bio receives Emergency Use Approval for Covid-19 vaccine in India
Gemcovac became the first saRNA vaccine to obtain approval for use in humans in India.
Pfizer and BioNTech enter $3.2bn deal with US Government for Covid-19 shots
This deal might comprise Omicron-adapted Covid-19 vaccines contingent on obtaining the US FDA authorisation.
Japan’s MHLW accepts GSK’s submission for shingles vaccine in adults
The filing is based on data from six clinical trials in subjects of the age 18 years and above.